These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 36071295)
1. Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment. Rasihashemi SZ; Sahrai H; Rezazadeh-Gavgani E; Yazdani Y; Khalaji A; Lotfinejad P Med Oncol; 2022 Sep; 39(12):183. PubMed ID: 36071295 [TBL] [Abstract][Full Text] [Related]
2. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets. Liang B; Hu X; Ding Y; Liu M J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291 [TBL] [Abstract][Full Text] [Related]
3. Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts. Khan NA; Asim M; Biswas KH; Alansari AN; Saman H; Sarwar MZ; Osmonaliev K; Uddin S J Exp Clin Cancer Res; 2023 Aug; 42(1):221. PubMed ID: 37641132 [TBL] [Abstract][Full Text] [Related]
4. Landscape of tumor and immune system cells-derived exosomes in lung cancer: mediators of antitumor immunity regulation. Castillo-Peña A; Molina-Pinelo S Front Immunol; 2023; 14():1279495. PubMed ID: 37915578 [TBL] [Abstract][Full Text] [Related]
5. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. Srivastava A; Rathore S; Munshi A; Ramesh R AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060 [TBL] [Abstract][Full Text] [Related]
6. The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation. Alfonsi R; Grassi L; Signore M; Bonci D Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652798 [TBL] [Abstract][Full Text] [Related]
7. Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response. Wu J; Zeng D; Zhi S; Ye Z; Qiu W; Huang N; Sun L; Wang C; Wu Z; Bin J; Liao Y; Shi M; Liao W J Transl Med; 2021 Sep; 19(1):381. PubMed ID: 34496872 [TBL] [Abstract][Full Text] [Related]
8. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383 [TBL] [Abstract][Full Text] [Related]
10. The role of exosomal PD-L1 in tumor progression and immunotherapy. Xie F; Xu M; Lu J; Mao L; Wang S Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023 [TBL] [Abstract][Full Text] [Related]
11. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer. Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744 [TBL] [Abstract][Full Text] [Related]
12. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Naseri M; Bozorgmehr M; Zöller M; Ranaei Pirmardan E; Madjd Z Oncoimmunology; 2020 Jun; 9(1):1779991. PubMed ID: 32934883 [TBL] [Abstract][Full Text] [Related]
13. Theranostic signature of tumor-derived exosomes in cancer. Kumar S; Dhar R; Kumar LBSS; Shivji GG; Jayaraj R; Devi A Med Oncol; 2023 Oct; 40(11):321. PubMed ID: 37798480 [TBL] [Abstract][Full Text] [Related]
14. Exosomes: small vesicles with big roles in hepatocellular carcinoma. Wu Z; Zeng Q; Cao K; Sun Y Oncotarget; 2016 Sep; 7(37):60687-60697. PubMed ID: 27463001 [TBL] [Abstract][Full Text] [Related]